Medicenna Therapeutics Corp.

MDNA

CA58490H1073

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 15:00:51 2024-05-17 EDT			5-day change	1st Jan Change
2.3 ^CAD	-2.95%		-6.88%	+447.62%

05-13	Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee	MT
05-13	Medicenna Brief: Providing Update on its Presentations at the 2024 ASCO Annual Meeting	MT

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Business Officer

October 27, 2023 at 08:19 am

Medicenna Therapeutics Corp. announced the departure of Jeff Caravella as Chief Business Officer, effective October 26, 2023.

Latest news about Medicenna Therapeutics Corp.

Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee	05-13	MT
Medicenna Brief: Providing Update on its Presentations at the 2024 ASCO Annual Meeting	05-13	MT
Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.	04-29	CI
Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding	04-25	CI
Medicenna Therapeutics Up 13% After Flagging Presentations	04-24	MT
Transcript : Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM	04-16
Medicenna Brief: Presenting Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of Phase 1/2 ABILITY-1 Study at 2024 Annual Meeting of the AACR	04-10	MT
Medicenna Therapeutics Presents Separate Updated Results and Preclinical Data; Shares Lost Near 12% Today	04-09	MT
Medicenna Brief: Comes After Its Shares Lost Near 12% today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And Masked Bi-Functional Anti-PD1-IL2 Superkine	04-09	MT
Medicenna Brief: Says Presented Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study	04-09	MT
Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study	04-09	CI
Medicenna Therapeutics Down 11% as it Presents Updated Preclinical Data on MDNA113 at AACR 2024	04-09	MT
Medicenna Brief: Says to Provide Clinical Update on MDNA11 ABILITY-1 Trial at Upcoming American Association for Cancer Research Annual Meeting	03-06	MT
Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting	03-06	CI
Medicenna Reports Q3 Net Loss $5.0 Million	02-14	MT
Medicenna Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Medicenna Brief: Net loss for the quarter ended December 31, 2023, was $5.0 million or ($0.07) per share compared to a net loss of $1.1 million or ($0.02) per share for the quarter ended December 31, 2022	02-14	MT
Medicenna Says First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda in Patients with Advanced Solid Tumors	02-13	MT
Medicenna Brief: Announcing First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Solid Tumors	02-13	MT
Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors	02-13	CI
Medicenna Commences Enrollment in ABILITY-1 Study Combining MDNA11 with Pembrolizumab	01-09	MT
Medicenna Brief: Commencing Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab	01-09	MT
Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck?s Pembrolizumab	01-09	CI
Medicenna Therapeutics Extends Period to Exercise Certain Warrants; Down 1.2%	12-22	MT
Medicenna Therapeutics Extends Period to Exercise Certain Warrants	12-22	MT

Chart Medicenna Therapeutics Corp.

Duration

Period

More charts

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Companyâs IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Companyâs early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Annual Meeting - Abstract No: 2709

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.37 CAD

Average target price

7 CAD

Spread / Average Target

+195.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MEDICENNA THERAPEUTICS CORP.	+447.62%	130M
MODERNA, INC.	+32.49%	50.85B
IQVIA HOLDINGS INC.	+0.23%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.93%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-22.13%	19.13B
BIO-TECHNE CORPORATION	+8.25%	13.05B
MEDPACE HOLDINGS, INC.	+27.57%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.59%	12.08B

Other Biotechnology & Medical Research